mTNBC
Jun 26, 2026
TRODELVY’s First-Line TNBC Approval: Gilead’s Big Bet Reshapes the TROP2 ADC Battlefield
Summary TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression. TRODELVY sets a new standard as Europe’s first ADC and first novel therapy in two decades for eligible patients with first-line metastatic triple-negative breast cancer. Approval was based on AS...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
